HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study

Adwoa K. A. Afrane1*, Bamenla Q. Goka1,2, Lorna Renner1,2, Alfred E. Yawson3, Yakubu Alhassan4, Seth N. Owiafe1, Seth Agyeman5, Kwamena W. C. Sagoe6 and Awewura Kwara7

Abstract

Background: Children living with human immunodeficiency virus (HIV) infection require lifelong effective antiretroviral therapy (ART). The goal of ART in HIV-infected persons is sustained viral suppression. There is limited information on virological non-suppression or failure and its associated factors in children in resource limited countries, particularly Ghana.

Methods: A cross-sectional study of 250 children aged 8 months to 15 years who had been on ART for at least 6 months attending the Paediatric HIV clinic at Korle Bu Teaching hospital in Ghana was performed. Socio-demographic, clinical, laboratory and ART Adherence related data were collected using questionnaires as well as medical records review. Blood samples were obtained for viral load and CD4+ count determination. Viral load levels > 1000 copies/ml on ART was considered virological non-suppression. Logistic regression was used to identify factors associated with virological non-suppression.

Results: The mean (±SD) age of the study participants was 11.4 ± 2.4 years and the proportion of males was 53.2%. Of the 250 study participants, 96 (38.4%) had virological non-suppression. After adjustment for significant variables, the factors associated with non-suppressed viral load were female gender (AOR 2.51 [95% CI 1.04–6.07], p = 0.041), having a previous history of treatment of tuberculosis (AOR 4.95 [95% CI 1.58–15.5], p = 0.006), severe CD4 immune suppression status at study recruitment (AOR 24.93 [95% CI 4.92–126.31], p < 0.001) and being on a nevirapine (NVP) based regimen (AOR 7.93 [95% CI 1.58–1.15], p = 0.005).

Conclusion: The prevalence of virological non-suppression was high. Virological non-suppression was associated with a previous history of TB treatment, female gender, severe CD4 immune suppression status at study recruitment and being on a NVP based regimen. Early initiation of ART and phasing out NVP-based regimen might improve viral load suppression in children. In addition, children with a history of TB may need focused measures to maximize virological suppression.

Keywords: Antiretroviral therapy, Paediatric HIV, Viral load, Virological non-suppression

* Correspondence: dadwoa@yahoo.com
1Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Human immunodeficiency virus (HIV) infection continues to be one of the most relevant infectious diseases [1, 2]. Antiretroviral therapy (ART) is a critical component of the overall management plan for HIV infection. The primary goal of ART is to suppress viral replication, which ultimately results in restoration of the immune system, reduction in HIV transmission and a general improvement in the quality of life of people infected with HIV [3, 4]. The World Health Organization (WHO) in 2013 recommended HIV viral load (HIV VL) monitoring as the gold standard for monitoring ART effectiveness in resource-limited settings [5]. This recommendation was adopted by Ghana in 2016. According to Ghana’s National AIDS Control Programme (NACP) guidelines, viral load testing is recommended 6 months after initiating ART and thereafter annually for people who have achieved virological suppression [6]. However, people with HIV VL levels > 1000 copies/ml are required to undergo intensified adherence support after which the viral load is repeated 3 months later in order to differentiate poor adherence from treatment failure [6].

Virological non-suppression could be due to poor adherence to ART, resistance to ART (transmitted or acquired) or pharmacokinetic issues (poor absorption, under-dosing and drug interactions) [7, 8]. ART regimen-related factors could result in the development of drug resistance [9, 10]. In addition, the delay in introduction of newer, more potent antiretrovirals with high barrier to drug resistance such as second-generation integrase strand transfer inhibitors (INSTIs) in resource-limited settings is a key contributing factor to virological non-suppression.

In previous studies a wide range of factors have been associated with virological non-suppression in children and these include socio-demographic factors such as younger age (less than 3 years) [11], male gender [12, 13], WHO advanced HIV stage [14, 15], co-infection with tuberculosis (TB) [16, 17], nevirapine (NVP) based therapy [18, 19], and poor adherence to treatment [20, 21]. Adherence to ART has always been a challenge for the paediatric population because drug formulations are often less tolerable, and may require dose adjustment as the child grows [22, 23]. Lack of a consistent caregiver in younger children and disclosure issues in adolescents also pose a challenge to medication adherence [22, 23]. These unique issues in children and adolescents can result in virological non-suppression, without the presence of drug resistance mutations [8].

High rates of virological non-suppression is common in children in low-and middle-income countries (LMICs) and could be due to poor medication adherence or treatment failure [8]. Identifying patients with virological non-suppression is important for intensified adherence counseling and increased frequency of follow up but it also an important sign of treatment failure especially in persons with good adherence [24]. The aim of this study was to determine the prevalence of virological non-suppression and its associated factors among children living with HIV (CLWH) attending a Paediatric HIV clinic at Teaching Hospital in Ghana. This knowledge would help to target interventions for improving virological suppression, reduce ART failure and ultimately improve clinical care of CLWH.

Methods

Study design and setting

This study used a cross-sectional design to recruit paediatric HIV positive patients attending the outpatient clinic from October 2017 to July 2018 at the Korle Bu Teaching Hospital (KBTH), Accra, Ghana. KBTH has 2500 beds and is currently the largest hospital in West Africa and the third largest on the African continent [25]. The hospital is the main tertiary referral centre in Accra and serves the majority of the Southern part of Ghana. The Paediatric HIV clinic at KBTH has been providing comprehensive HIV/AIDS care and management services since 2004. Patients are referred from primary and secondary health facilities as well as from other departments within the hospital. An average of 40 patients are seen per clinic day. The National AIDS Control Program (NACP) provides ART medication free of charge. HIV VL and CD4+ counts are also paid for by the program. The clinic uses national treatment guidelines that are in line with current WHO recommendations for ART [26]. Treatment is initiated for all patients irrespective of the CD4+ count. Antiretroviral drugs available and in use in various combinations at the clinic at the time of the study were zidovudine (AZT), lamivudine (3TC), abacavir (ABC), efavirenz (EFV), nevirapine (NVP), tenofovir (TDF), and ritonavir boosted lopinavir (LPV/r).

Study participants

Study participants were CLWH aged between 8 months and 15 years and who had been on ART for at least 6 months. Children who had been transferred from referral points and did not have their previous notes available and children with HIV-2 mono infection were excluded from the study because currently, there are no FDA-approved assays for quantification of HIV-2 RNA. Voluntary informed consent was obtained from parents and guardians of study participants and assent from children aged 10-15 years. Before seeking informed consent/assent, study participants were screened to determine whether they were eligible or not. A questionnaire was administered to study participants and caregivers. Information was also collected retrospectively from their medical records.
Sample size determination
The Cochran’s sample size formula [27] was used to calculate the sample size to determine the prevalence of non-suppressed viremia. A minimum sample size of 250 study participants was determined using confidence level of 95% and an error margin of 5%. Consecutive cases of HIV children who met the eligibility criteria were enrolled into the study until the sample size was reached.

Data collection
Participants had their drug doses checked for appropriateness of their current drug regimen. The dosage, (frequency and dose/kg or m²) was cross checked with the recommended dosage and appropriateness was documented as ‘yes’ or ‘no.’ ART Adherence was assessed by a pharmacist on the day of recruitment of the study participant using the pill count and this is usually done at every appointment visit.

Pill count (the number of pills taken) was calculated based on the expected number of pills that the care giver brought back when refilling their ART medication on the day of study recruitment [28]. Total refill was the expected number of pills to have been taken since the last visit.

Pill count was calculated as: Total refill - Pill left.

Percentage adherence was calculated as \( \frac{\text{Pill count}}{\text{Total Refill}} \times 100\% \)

Laboratory analysis
Laboratory investigations done on the day of recruitment were CD4⁺ count and HIV VL. CD4⁺ absolute cell count and cell percentage were quantified by a dual-platform flow cytometry technology using a FACS Count system (Becton-Dickinson, Franklin Lakes, NJ, USA) according to manufacturer’s instructions at the Fevers Unit Laboratory of KBTH. The HIV RNA VL testing was performed at the Central Laboratory of KBTH using the COBAS® AMPLICOR Monitor test (Roche Diagnostic Systems, Branchburg, NJ, USA), with a lower limit of detection of 20 copies/ml. The laboratory at the Fevers unit and the Central Lab KBTH are certified by the South African Public Health Reference Laboratory and participates in an external quality assurance testing programme by the South African Public Health Reference Laboratory.

Operational definitions
In accordance with WHO guidelines, study participants were categorized as having virological non-suppression if the HIV VL level was >1000 copies/ml on the day of recruitment, after at least 6 months of using ART. Drug Adherence was determined by caregivers report and categorized according to WHO guidelines as follows: Good ≥95%; Fair: 85–94%; Poor < 85% [29].

Statistical analysis
The dependent variable was virological non-suppression (VL > 1000 copies/ml). The independent variables were the sociodemographic factors, clinical factors and ART Adherence factors. Pearson’s chi-square test of association was used to determine strength of association between the independent categorical variables and the outcome variable (virological non-suppression). The logistic regression model was used in determining the factors influencing HIV VL suppression among study participants with statistical significance set at p < 0.05. With the exception of age of the child which was included in the binary logistic regression model because of known associations in the literature [8, 11], all other variables p-values < 0.10 from the Pearson’s chi-square test were included. The crude odds ratio (OR) and adjusted odds ratio (AOR) were determined and their respective 95% confidence intervals were calculated.

Ethical considerations
Ethical approval (KBTH-IRB/ 00060/2017) was obtained from the Institutional Review Board of Korle Bu Teaching Hospital, Accra, Ghana. Informed consent was obtained from parents or legal guardians for each minor participant prior to enrolment to participate in the study.

Results
Baseline characteristics
The baseline characteristics of the study participants are shown in Table 1. Of the 250 participants, 59.2% were within the age range of 10 to 15 years and 53.2% were males. Overall, 46.0% of primary caregivers who were mothers 44% guardians (grandmother, grandfather, aunt, uncle, foster caregiver) and only 10% were fathers. The educational and occupation of parents is described in Table 1. Overall, the mothers of 157 (62.8%) participants were HIV positive while 93 (37.2%) of mothers had unknown HIV status. The unknown status included parents who were dead. The fathers of 62 (24.8%) study participants were HIV positive whilst 105 (42.0%) were HIV negative and 83 (33.2%) had unknown HIV status.

Clinical and laboratory details of study participants
Of all participants, 71 (28.4%) had a history of previous TB treatment and 97 (38.8%) had WHO clinical stage 1 disease at initiation of ART.

Baseline VL and CD4⁺ count of study participants
Out of the 250 study participants, only 74 (30%) had baseline VL documented. Of the 74 study participants
Table 1 Baseline characteristics of patients according to virological suppression status

| Characteristics                                                                 | All patients | VL at study recruitment (copies/ml) | chi² | P value |
|---------------------------------------------------------------------------------|--------------|-------------------------------------|------|---------|
|                                                                                |              | Suppressed (≤ 1000) | Non suppressed (> 1000) |      |         |
|                                                                                | N (%)        | n (%)                 | n (%)           |      |         |
| Age category (N = 250)                                                         |              |                      |                  |      |         |
| < 5 years                                                                       | 30 (12.0)    | 16 (53.3)             | 14 (46.7)        | 1.1  | 0.576   |
| 5 to < 10 years                                                                | 72 (28.8)    | 44 (61.1)             | 28 (38.9)        |      |         |
| 10 to 15 years                                                                 | 148 (59.2)   | 94 (63.5)             | 54 (36.5)        |      |         |
| Sex of child (N = 250)                                                         |              |                      |                  | 4.43 | 0.035*  |
| Female                                                                         | 117 (46.8)   | 64 (54.7)             | 53 (45.3)        |      |         |
| Male                                                                           | 133 (53.2)   | 90 (67.7)             | 43 (32.3)        |      |         |
| Primary caregiver relationship to subject (N = 250)                             |              |                      |                  | 2.15 | 0.499   |
| Mother                                                                         | 115 (46.0)   | 45 (39.1)             | 70 (60.9)        |      |         |
| Father                                                                         | 25 (10.0)    | 12 (48.0)             | 13 (52.0)        |      |         |
| Guardian                                                                       | 110 (44.0)   | 50 (45.5)             | 60 (54.5)        |      |         |
| Educational status of father (N = 192)                                          |              |                      |                  | 4.16 | 0.527   |
| None                                                                           | 19 (9.9)     | 11 (57.9)             | 8 (42.1)         |      |         |
| Basic (Primary/JHS/Middle)                                                     | 65 (33.9)    | 36 (40.0)             | 29 (60.0)        |      |         |
| Secondary                                                                      | 82 (42.7)    | 53 (64.6)             | 29 (35.4)        |      |         |
| Tertiary                                                                        | 26 (13.5)    | 19 (73.1)             | 7 (26.9)         |      |         |
| Educational status of mother (N = 168)                                         |              |                      |                  | 1.27 | 0.938   |
| None                                                                           | 27 (16.1)    | 15 (55.6)             | 12 (44.4)        |      |         |
| Basic (Primary/JHS/Middle)                                                     | 94 (56.0)    | 59 (64.0)             | 35 (36.0)        |      |         |
| Secondary                                                                      | 36 (21.4)    | 23 (63.9)             | 13 (36.1)        |      |         |
| Tertiary                                                                        | 11 (6.5)     | 8 (72.7)              | 3 (27.3)         |      |         |
| Occupational class of father (N = 192)                                         |              |                      |                  | Φ    | 0.541   |
| Professional                                                                   | 2 (1.0)      | 2 (62.5)              | 0 (37.5)         |      |         |
| Other                                                                          | 187 (97.4)   | 115 (61.5)            | 72 (38.5)        |      |         |
| Unemployed                                                                      | 3 (1.6)      | 2 (76.5)              | 1 (23.5)         |      |         |
| Occupational class of mother (N = 168)                                         |              |                      |                  | Φ    | 0.73    |
| Professional                                                                   | 0 (0.0)      | 0 (0.0)               | 0 (0.0)          |      |         |
| Other                                                                          | 151 (60.4)   | 90 (59.5)             | 61 (40.5)        |      |         |
| Unemployed                                                                      | 17 (6.8)     | 11 (66.7)             | 6 (33.3)         |      |         |
| HIV status of father (N = 250)                                                 |              |                      |                  | 1.83 | 0.401   |
| Negative                                                                       | 105 (42)     | 62 (59.0)             | 43 (41.0)        |      |         |
| Positive                                                                       | 62 (24.8)    | 36 (58.1)             | 26 (41.9)        |      |         |
| Unknown                                                                        | 83 (33.2)    | 56 (67.5)             | 27 (32.5)        |      |         |
| HIV status of mother (N = 250)                                                 |              |                      |                  | 1.97 | 0.373   |
| Negative                                                                       | 10 (4)       | 8 (80.0)              | 2 (20.0)         |      |         |
| Positive                                                                       | 157 (62.8)   | 98 (62.4)             | 59 (37.6)        |      |         |
| Unknown                                                                        | 83 (33.2)    | 48 (57.8)             | 35 (42.2)        |      |         |
| Clinical and Lab Variables                                                     |              |                      |                  |      |         |
| TB treatment in the past (N = 250)                                             |              |                      |                  | 2.74 | 0.098   |
| No                                                                             | 179 (71.6)   | 116 (64.8)            | 63 (35.2)        |      |         |
| Yes                                                                            | 71 (28.4)    | 38 (53.5)             | 33 (46.5)        |      |         |
Table 1 Baseline characteristics of patients according to virological suppression status (Continued)

| Characteristics                                      | All patients | VL at study recruitment (copies/ml) | Non suppressed (> 1000) |
|-------------------------------------------------------|--------------|------------------------------------|------------------------|
|                                                       | N (%1)       | n (%)2                             | n (%)2                 |
| WHO stage at ART initiation (N = 250)                 |              |                                    |                        |
| Stage 1                                               | 97 (38.8)    | 64 (66.0)                          | 33 (34.1)              |
| Stage 2                                               | 68 (27.2)    | 42 (61.8)                          | 26 (38.3)              |
| Stage 3                                               | 63 (25.2)    | 35 (55.6)                          | 28 (44.4)              |
| Stage 4                                               | 22 (8.8)     | 13 (59.1)                          | 9 (40.9)               |
| Baseline VL (N = 74)                                  |              |                                    |                        |
| < 10,000                                              | 30 (40.5)    | 22 (73.3)                          | 8 (26.7)               |
| 10,000 to 99,999                                      | 22 (29.7)    | 13 (60.0)                          | 9 (40.0)               |
| 100,000 to 499,999                                    | 12 (16.2)    | 8 (66.7)                           | 4 (33.3)               |
| > 499,999                                             | 10 (13.5)    | 7 (70.0)                           | 3 (30.0)               |
| Baseline CD4+ Immune suppression status (overall) (N = 225) |              |                                    |                        |
| Severe                                                | 35 (15.6)    | 23 (65.7)                          | 12 (34.3)              |
| Advanced                                              | 25 (11.1)    | 17 (68.0)                          | 8 (32.0)               |
| Mild                                                  | 18 (8.0)     | 12 (66.7)                          | 6 (33.3)               |
| none                                                  | 147 (65.3)   | 90 (61.2)                          | 57 (38.8)              |
| CD4+ Immune suppression status at study recruitment (overall) (N = 230) |              |                                    |                        |
| Severe                                                | 24 (10.4)    | 7 (29.2)                           | 16 (66.7)              |
| Advanced                                              | 18 (7.8)     | 1 (38.9)                           | 11 (61.1)              |
| Mild                                                  | 23 (10.0)    | 12 (52.1)                          | 11 (47.8)              |
| normal                                                | 165 (71.7)   | 115 (73.3)                         | 44 (26.7)              |
| Art Related Variables                                 |              |                                    |                        |
| Duration of ART (N = 250)                             |              |                                    |                        |
| < 12 months                                           | 32 (12.8)    | 17 (53.1)                          | 15 (46.9)              |
| 12–23 months                                          | 31 (12.4)    | 19 (61.2)                          | 12 (38.8)              |
| 24–36 months                                          | 23 (9.2)     | 15 (65.2)                          | 8 (34.8)               |
| 36–47 months                                          | 20 (8.0)     | 13 (65.0)                          | 7 (35.0)               |
| 49–50 months                                          | 19 (7.6)     | 10 (52.6)                          | 9 (47.4)               |
| > 59 months                                           | 125 (50.0)   | 80 (64.0)                          | 45 (36.0)              |
| Current ART regimen (N = 250)                          |              |                                    |                        |
| Nevirapine based                                      | 68 (27.2)    | 34 (50)                            | 34 (50.0)              |
| Efavirenz based                                       | 173 (69.2)   | 114 (65.9)                         | 59 (34.1)              |
| Second line drug                                      | 9 (3.6)      | 6 (66.7)                           | 3 (33.3)               |
| Adherence (Pill count percentage rate) (N = 250)       |              |                                    |                        |
| Poor adherence (85%)                                  | 58 (23.2)    | 29 (50)                            | 29 (50.0)              |
| Fair adherence (85–94%)                               | 41 (16.4)    | 32 (78.0)                          | 9 (22.0)               |
| Good adherence (≥ 95%)                                | 151 (60.4)   | 93 (61.6)                          | 58 (38.4)              |
| Person responsible for child’s medication (N = 250)    |              |                                    |                        |
| Mother only                                           | 132 (52.8)   | 82 (62.1)                          | 50 (37.9)              |
| Father only                                           | 25 (10.0)    | 13 (52.0)                          | 12 (48.0)              |
| Both parents                                          | 12 (4.8)     | 5 (41.7)                           | 7 (58.3)               |

χ² P value

| WHO stage at ART initiation (N = 250) | 1.82 | 0.611 |
| Baseline VL (N = 74) | Φ | 0.751 |
| Baseline CD4+ Immune suppression status (overall) (N = 225) | 1.36 | 0.71 |
| CD4+ Immune suppression status at study recruitment (overall) (N = 230) | Φ | <0.001* |
| Duration of ART (N = 250) | 2.15 | 0.828 |
| Current ART regimen (N = 250) | 5.32 | 0.07 |
| Adherence (Pill count percentage rate) (N = 250) | 7.99 | 0.018* |
| Person responsible for child’s medication (N = 250) | 4.55 | 0.336 |
that had records of baseline VL, the median (range) \( \log_{10} \) copies/ml was 4.8 (1.7–6.9). The breakdown of baseline VL level is shown in Table 1. Of the 74 participants with baseline VL, 30 (40.5%), had baseline VL < 10,000 copies/ml, and 10 (13.5%) had viral load levels \( \geq 500,000 \) copies/ml. Overall, of the 225 study participants that had records for their Baseline CD4\(^+\) counts, 35 (15.6%) had severe CD4 immune suppression status (CD4 < 15% / CD4\(^+\) count < 200 cells/mm\(^3\)), 25 (11.1%) had advanced CD4 immune suppression status (CD4\(^+\): 15–19% / CD4\(^+\) count: 200–349 cells/mm\(^3\)), 18 (8%) had mild CD4 immune status (CD4\(^+\): 20–25% / CD4\(^+\) count: 350–499 cells/mm\(^3\)) with the majority of study participants 147 (65.3%) having normal CD4\(^+\) status (CD4 > 25% / CD4\(^+\) count: >500 cells/mm\(^3\)) [3].

**CD4\(^+\) count at study recruitment**

The CD4\(^+\) results for 20 of the study participants were not available because of technical issues that occurred with their blood samples at the laboratory. Of the 230 that had CD4\(^+\) results on the day of study recruitment, 10 (4.3%) were children less than 5 years and 220 (95.7%) were children between 5 and 15 years of age. For the overall CD4\(^+\) immune suppression status, 24 (10.4%) had severe immune suppression status, (CD4 < 15% / CD4\(^+\) count < 200 cells/mm\(^3\)), 18 (7.8%) had advanced immune suppression status (CD4\(^+\): 15–19% / CD4\(^+\) count: 200–349 cells/mm\(^3\)), 23 (10%) had mild immune suppression status (CD4\(^+\): 20–25% / CD4\(^+\) count: 350–499 cells/mm\(^3\)) and 165 (71.7%) had normal CD4\(^+\) immune status (CD4\(^+\): >25% / CD4\(^+\) count: >500 cells/mm\(^3\)) [3].

**Proportion of patients with virological non-suppression**

At study enrolment, the mean (± SD) duration on ART was 64 months ±3.0 months. Overall, 96 (38.4%) of the 250 participants had virological non-suppression (VL > 1000 copies/ml). Of the 96 participants with virological non-suppression, 20 (20.8%) had VL > 100,000 copies/ml. Overall, 96 (38.4%) of the 250 participant had VL levels <20 copies/ml and 58 (23.2%) had low-level viraemia (VL levels of 20–1000 copies/ml). For virological non-suppression within the various age groups, 14 (46.7%) were within the age group (<5 years), 28 (38.9%) were within the age group (5–9 years) and 54 (36.5%) were within the age group (10–15 years).

**Factors associated with virological non-suppression**

Bivariate analysis of factors associated with virological non-suppression are shown in Table 1. Females were more likely to have virological non-suppression in comparison to males (54.2% vs 32.2%, \( p = 0.035 \)). The overall CD4\(^+\) immune suppression status of the subject at study recruitment showed a significant association with the subjects VL. (Fischer’s exact, \( p < 0.001 \)). The adherence rate of subject measured by pill count percentage showed a significant association with the subjects VL (χ\(^2\) = 7.99, \( p = 0.018 \)).

There were no significant differences for the following variables: age of subject, primary caregiver’s relationship to subject, educational status of father, educational status of mother, occupational status of mother, occupational status of father, educational status of subject, primary caregiver’s relationship to subject, educational status of father, educational status of mother, occupational status of mother, history of previous TB treatment, WHO stage at initiation of ART, baseline VL and baseline CD4\(^+\) count values (overall), duration on ART, current ART regimen and person responsible for child’s medication (Table 1).

**Factors associated with virological non-suppression in multivariate analysis**

In multivariate analysis of patients, females were 2.5 times more likely to have virological non-suppression when compared with male study participants (AOR 2.51 [95% CI 1.04–6.07], \( p = 0.041 \)). Additionally, study participants with severe CD4\(^+\) immune suppression status at study recruitment were 25 times more likely to have virological non-suppression when compared to children with normal CD4\(^+\) / no immune suppression in multivariate analysis (AOR 24.93 [95% CI 4.92–126.31], \( p < 0.001 \)). Participants with a prior history of TB treatment were 4.95 times more likely to have virological non-suppression as compared to participants without a prior history of TB treatment (AOR 4.95 [95% CI 1.58–15.5], \( p < 0.006 \)). Participants with a NVP based regimen was 7.93 times more likely to be associated with virological non-suppression (AOR 7.93 [95% CI 1.58–15.5], \( p = \) ...
0.005). Multivariate analysis of adherence pill count did not yield any significant results (Table 2).

**Discussion**

In this cross-sectional study, a relatively large proportion of the 250 CLWH (38%) had virological non-suppression after being on ART for a mean period of 64 months. This translates to a virological suppression rate of 62% and is similar to the estimate made by Ghana with respect to its achievement of the third 90 of the UNAIDS 90–90-90 targets. The high rate of non-suppression suggest that intensified efforts to improve HIV treatment in CLWH is needed to achieve the current 95–95-95 targets proposed by UNAIDS with the purpose of ending AIDS by 2030 [30]. Female gender, having a previous history for TB treatment, severe CD4+ immunodeficiency status at study recruitment and a NVP-based regimen were associated with virological non-suppression. Some factors identified in other studies such as adherence to ART, clinical stages 3 and 4, parent’s educational level and their employment status were not significant in this current study.

As antiretroviral access continues to expand in resource-limited countries like Ghana, monitoring response to ART by the use of VL measurements is critical in determining the effectiveness of ART in the population [31]. The Sub-Saharan African region’s prevalence for virological non-suppression (>1000 copies/ml) in children who have been on ART for at least 6 months ranges from 13 to 44% [8, 24, 32]. A virological non-suppression rate of 38% found in this study is concerning given the risk for the emergence of ART resistance and subsequently failure of the ART regimen, necessitating a switch to second, or later third line treatment [8]. This ultimately would result in an increase in morbidity and mortality of the CLWH and cause the spread of resistant viruses [8]. Given these consequences, VL monitoring per national guidelines should be routinely done in all children on ART and those identified as being virologically non-suppressed, should have adherence

| Table 2 Univariate and multivariate analysis of factors associated with virological non-suppression in CLWH on ART for at least 6 months (N = 250) |
|---------------------------------------------------------------|
| **Factor**                                                    | **Univariate analysis** | **Multivariate analysis** |
|                                                              | **UOR (95% CI)**         | **AOR (95% CI)**          |
|                                                              | **P value**              | **P value**               |
| **Sex of child**                                             |                          |                            |
| Male                                                        | ref                      |                            |
| Female                                                      | 2.52 1.35–4.67           | 2.51 1.04–6.07             |
| **Age category**                                             |                          |                            |
| <5 years                                                    | 1.72 0.57–5.24           | 2.18 0.23–20.89            |
| 5 to <10 years                                              | 1.57 0.78–3.17           | 2.84 1.01–8.05             |
| 10 to 15 years                                              | ref                      | ref                       |
| **CD4+ Immune suppression status at study recruitment**      | <0.001*                  | <0.001*                   |
| Severe                                                      | 9.03 3.08–26.51          | 24.93 4.92–126.31          |
| Advanced                                                    | 7.97 2.03–31.31          | 9.2 1.27–66.48             |
| Mild                                                        | 3.65 1.35–9.9            | 3.75 0.91–15.4             |
| None                                                        | ref                      | ref                       |
| **TB treatment in the past**                                |                          |                            |
| No                                                          | ref                      | ref                       |
| Yes                                                        | 1.67 0.87–3.18           | 4.95 1.58–15.5             |
| **Current Drug**                                            |                          |                            |
| Efavirenz based                                             | ref                      | ref                       |
| Nevirapine based                                            | 1.79 0.9 – 3.52          | 7.93 2.26–27.86            |
| Second line drug                                            | 0.86 0.15–4.86           | 1.02 0.09–11.8             |
| **Pill count rate**                                         | **0.012***               | **0.264**                 |
| Good adherence                                              | ref                      | ref                       |
| Fair adherence                                              | 0.3 0.1–0.93             | 0.43 0.11 – 1.69           |
| Poor adherence                                              | 1.93 0.92–4.03           | 1.65 0.54 – 5.01           |

*p < 0.05*
counselling and then a repeat viral load level to confirm if they have virological failure. Once virological failure has been confirmed then the regimen switch should occur according to Standard Treatment Guidelines outlined by NACP [6].

Routine VL monitoring is also important for early detection of treatment failure due to pre-treatment drug resistance (PDR), which is known to compromise the efficacy of ART at an individual and population level [33]. Bavara et al using a large database created for surveillance of HIV-1 drug resistance in Italy confirmed that having more than one PDR is an important predictor of virological failure [33]. This phenomenon is on the increase and has also been reported in sub-Saharan Africa [34, 35] Latin America [36] and Asia [37]. While PDR can be detected through baseline genotypic resistance testing (GRT) prior to initiation of ART, it is expensive and not performed at patient entry in care low- and middle-income countries [9]. Currently, VL monitoring has been a programmatic challenge at our Paediatric HIV clinic due to frequent interruptions in the availability of resources required by the laboratory, resulting in erratic provision of services. Adequate funding and improved logistics management to ensure uninterrupted VL testing in the laboratory would boost the implementation of the VL monitoring protocol that exists in the clinic.

The rate of non-suppression children could be due to a number of reasons, depending on the settings. We observed that females were 2.5 times more likely to have virological non-suppression as compared to males. This phenomenon was similar to the study by Muri et al [38], in Tanzanian children, whereby females were also 2.5 more times likely to have virological non-suppression. On the contrary, some studies have reported that males had increased odds of virological non-suppression [13, 39], whilst other studies however found no association between sex and virological non-suppression [40]. The role of gender in virological suppression could be biologic according to authors such as Njom et al. [41]. The relationship of virological suppression and gender is therefore inconclusive and requires further studies.

A third of our study population had been previously treated for TB. We found that having a history of previous TB treatment increased the odds of having virological non-suppression by as much as five times. These findings are in agreement with studies reported by Ahoua et al [42], and by Rajin et al. [43]. On the other hand, it has been recently reported that children who had a history of TB co-infection had better virological outcomes [13]. Reasons for this could be due to the close monitoring, frequent clinic visits and adherence support, adopted as part of TB treatment offered at the sample sites. The association of a previous history of TB and virological non-suppression in this current study could be due to the increased pill burden and drug-drug interactions between the medications for TB and HIV therapies, especially the NNRTIs or PIs in the setting of rifampin-containing TB treatment. The significance of TB comorbidity on the occurrence of virological non-suppression buttresses the need for the prioritization of frequent VL monitoring and adherence support in TB/HIV co-infected patients as well as patients who have a history of previous TB. While we were not able to examine the effect of other opportunistic infections (OIs) in this study, it is important to note that non-TB opportunistic infections are now less common than in the past because of early HIV diagnosis and initiation of effective ART. As a result, there is reduction of OI-related morbidity and mortality in person with HIV [44].

The odds of virological non-suppression was almost eight times more likely in study participants whose current drug regimen was NVP-based as compared to a study participant who had an EFV-based regimen. The findings of this study is consistent with current literature that shows that patients on NVP-based regimens experienced more virological failure than patients on EFV-based regimens [18, 19]. The use of regimens containing NVP is associated with a low genetic barrier of drug resistance and a higher risk of baseline resistance in cases where NVP was used as prophylaxis in the babies for Prevention of Mother To Child Transmission (PMTCT). This current study however did not evaluate prior NVP exposure. Our findings support the current ART guidelines being used at the HIV clinic at KBTH which is to phase out NVP based regimens and replace with LPV/r or EFV regimens for children less than 20 kg. Current guidelines recommend a Darulagatavir (DTG) based regimen as the preferred first-line for children weighing at least 20 kg. Hopefully with the introduction of DTG and its scale up, the non suppression due to certain antiretroviral drugs such as NVP will be reduced.

We observed that study participants found to have severe CD4+ immune suppression status at the time of study recruitment were 25 times more likely to have virological non-suppression. These findings are in congruence with studies reported by Jobanputra et al [40], among children in Swaziland and by Izudi et al [45], among children in Northwestern Uganda where it was found that patients with low CD4+ count values at study recruitment were more likely to have virological non-suppression. This finding is expected and supports the knowledge that viral suppression leads to immune recovery and could reflect the fact that those study participants who were virologically suppressed had a chance to reconstitute their immune systems for their CD4+ counts to increase [46]. This finding also supports early initiation of ART in children and according to the
current ART guideline in Ghana, all children confirmed to have HIV diagnosis after birth are started on ART regardless of the CD4+ count.

There was no association between parent-educational level, employment status of parent and virological non-suppression in this study. This is in agreement with a Danish HIV Cohort reported by Legarth et al. [47] which also showed no association between education level and virological non-suppression. This finding is however in contrast to a study reported by Mensah et al. [48] in Ghana, in which a child with an unemployed caregiver was five times more likely to have virological non-suppression. There is substantial evidence on the socio-economic inequalities in the treatment outcomes of chronic diseases like HIV. This current study could not confirm association between employment status and virological non-suppression. This observation could be due to the fact that for almost a third of study participants, the educational and employment status of parents was not known.

Studies on the relationship between self-reported adherence to ART and virological non-suppression have shown inconsistent results [20, 49]. In this study, adherence level measured by pill count was not associated with virological non-suppression. On the other hand in a clinical trial reported by Intasan et al. [50], in Cambodian children, non-adherence was associated with virological non-suppression. The measure of adherence used in the study by Intasan et al. [50], was however the 3 day self-report by caregiver. In a more recent research by Natukunda et al. [24], in adolescents, reported in 2019, more than 70% of adolescents who experienced virological non-suppression were sufficiently adherent as measured by pill count (adherence > 95%). On the other hand, there are also studies whereby poorly adherent patients maintained undetectable VL [49, 51].

Children with low level viraemia (LLV) with detectable viral loads above 20 copies/ml but less than 1000 copies/ml was common (23%) in this study. Thus, these children have the risk of continuing on a failing regimen for a considerable time, especially given that VL are regularly done once a year. There is therefore the need to design algorithms for patients with LLV to have more frequent VL monitoring as literature has shown the emergence of high-level resistance in this group of individuals.

The strength of this current study is that it did not only determine the prevalence of virological non-suppression but explored factors associated with the phenomenon in children. In the absence of drug resistance testing information, close monitoring of VL levels, multidisciplinary support and prompt clinical judgment are key in ensuring children who have failed treatment are appropriately transitioned to second line therapy. Ultimately, an ounce of prevention is better than a pound of cure.'

Limitation
The reliance on self-reported data as a measure of adherence, which may be affected by recall and social desirability bias. Analysis of baseline VL and CD4+ count was not available for some of the subjects and hence analysis on baseline VL and CD4+ could not be done for those patients. This is because VL monitoring was started in April 2011 (as a national policy) and hence all children above 8 years of age did not have the opportunity of having a baseline VL level done.

Conclusion
The high rate of virological non-suppression is consistent with findings in other countries in Sub-Saharan setting and emphasizes the great challenge to successfully suppressing HIV in paediatric patients and reinforces the need for regular monitoring of viral load levels in children. Patients on ART with active TB and those with a history of previous TB should be prioritized for more regular VL monitoring (6 monthly) as the national guidelines advocate for yearly monitoring of viral load for patients whose viral load levels are suppressed. Further research should focus on determining resistance patterns in this study population.

Acknowledgments
The following people have contributed in diverse ways to the study, Prof. Yaw Afrane, Rev. (Prof.) John Appiah-Poku, Prof Margaret Larney, Dr. Nyonuqu Akosua Baddoo, Dr. Timothy Archampong, Dr. Emilia Udofo, Dr. Frank Owusu Sekyere, Dr. Bola Ozoza, Dr. Jocelyn Darme, Dr. Claire Keane, Dr. Abena Takyi, Mr. Isaac Boamah, Miss Christabel Siaw-Akugbey, Mr. Derrick Tetteh, Mrs. Obedia Seneake, Miss Sarah Brew and Mr. Shittu Dhikrullahi. I also acknowledge the UG-UF D43 training grant that supported me to take a course in research proposal development for this study.

Abbreviations
ABC: Abacavir; AIDS: Acquired Immunodeficiency Syndrome; AOR: Adjusted Odds Ratio; ART: Antiretroviral Therapy; CD4: Cluster of differentiation 4; CD4%: CD4 percentage; CLWH: Children Living with HIV; DTG: Dolutegravir; EFV: Efavirenz; ELISA: Enzyme-linked immunosorbent assay; FDA: Food and Drug Administration; HIV: Human Immunodeficiency Virus; HIV VL: HIV viral load; KBFH: Korle Bu Teaching Hospital; LMIC: Low- and middle-income countries; LLV: Low level viraemia; LPV/r: Ritonavir boosted lopinavir; NACP: National AIDS Control Programme; NVP: Nevirapine; PCR: Polymerase Chain Reaction; PDR: Pre-treatment Resistance; PI: Protease Inhibitor; SPSS: Statistical Package for Social Sciences; TEN: Tenofovir; TB: Tuberculosis; VL: HIV-1 RNA Viral Load; U.O.R: Unadjusted Odds Ratio; WHO: World Health Organization; ZDV: Zidovudine; 3TC: Lamivudine

Authors’ contributions
AKAA contributed to conception and study design, acquisition of data, analysis and interpretation of data and drafting of the manuscript. AK, BG, LR contributed to study design, interpretation of data and substantively revised it. SA contributed to acquisition of data. SA contributed to laboratory testing. YA contributed to analysis of data and interpretation of data. AEF contributed to analysis of data, interpretation of data and substantively revised it. KWCS contributed to conception and study design, interpretation of data and substantively revised it. All authors read and approved the final manuscript.
Funding
AKAA and AK received support from University of Florida-University of Ghana Training Program in Tuberculosis and HIV Research in Ghana funded by Fogarty International Center at the National Institutes of Health (grant number D43 TW010055) for training.

Availability of data and materials
The data sets used and analysed during this study are available with the corresponding author on request.

Declarations

Ethics approval and consent to participate
Ethical approval (KETH-IRB/ 00060/2017) was obtained from the Institutional Review Board of Korle Bu Teaching Hospital, Accra, Ghana. An informed consent was obtained from parents or legal guardians for each minor participant prior to enrolment to participate in the study. All procedures performed involving study participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
All authors declare that there are no competing interests.

Author details
1Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana.
2Department of Child Health, University of Ghana Medical School, Accra, Ghana.
3Department of Community Health, University of Ghana Medical School, Legon, Accra, Ghana.
4Department of Health Policy Planning and Management, School of Public Health, University of Ghana, Legon, Accra, Ghana.
5Department of Immunology, Korle Bu Teaching Hospital, Accra, Ghana.
6Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana.
7Department of Medicine, University of Florida, College of Medicine, Gainesville, Florida, USA.

Received: 21 April 2021 Accepted: 21 July 2021
Published online: 02 August 2021

References
1. History of HIV and AIDS overview | Avert. https://www.avert.org/professiona ls/history-hiv-aids/overview (Accessed 26 Dec 2019).
2. HIV/AIDS Facts, Prevention, Signs, Symptoms & Medications. eMedicineHealth. https://www.emedicinehealth.com/hivaids/article_em.htm (Accessed 26 Dec 2019).
3. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7(1):13. https://doi.org/10.1542/peds.2007-0273.
4. Aids C on P, Health S on IC. Increasing antiretroviral drug access for children with HIV infection. Pediatrics. 2007;119(4):838–45. https://doi.org/10.1542/peds.2007-0273.
5. WHO | Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. WHO. http://www.who.int/hiv/pub/guidelines/keypopulations-2016/en/ (Accessed 20 Sep 2016).
6. National AIDS/STI Control Programme, Ghana Health Service. 2016 HIV Sentinel Survey Report 2016.
7. talent maphosa. 6. hiv antiretroviral resistance. 14:27:59 UTC.https://www.slideshare.net/talentmaphosa6/hiv-antiretroviral-resistance (Accessed 26 Dec 2019).
8. Bulage L, Ssewanyana I, Nakabivina V, Nsbuga F, Khembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014–July 2015. BMC Infect Dis. 2017;17(1):326. https://doi.org/10.1186/s12879-01 7-2428-3.
9. WHO | Global action plan for HIV drug resistance 2016-2021. https://www. who.int/hiv/pub/drugresistance/hiv-drug-resistance-brief-2016/en/ (Accessed 13 Feb 2019).
10. Hamers RL, de Wit TFR, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5(10):e588–96. https://doi.org/10.1016/S2352-3018(18)30173-5.
11. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12(1):197. https://doi.org/10.1186/1471-2334-12-197.
12. Janssens B, Raleigh B, Soeung K, Akoa K, Te V, Gupta J, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120(5):e1134–40. https://doi.org/10.1542/peds.2006-3503.
13. Kadima J, Patterson E, Mbou M, Blat C, Nyandumako M, Bukusi EA, et al. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya. PLoS One. 2018;13(11):e0200242. https://doi.org/10.1371/journal.pone.0200242.
14. Rupérez M, Pou C, Maculube S, Cedeño S, Luís L, Rodríguez J, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70(9):2639–47. https://doi.org/10.1093/jac/dkv143.
15. Yassin S, Gebretakelie GB. Magnitude and predictors of antiretroviral treatment failure among HIV-infected children in fiche and Kuyu hospitals, Oromia region, Ethiopia: a retrospective cohort study. Pharmacol Res Perspect. 2017;5(1):e00296. https://doi.org/10.1016/j.prp2.296.
16. Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangwendi P, et al. Tuberculosis risk factors and mortality for HIV infected persons receiving antiretroviral therapy in South Africa. AIDS Lond Engl. 2010;24(12):1849–55. https://doi.org/10.1097/QAD.0b013e32832a3507.
17. Costenaro P, Penazzato M, Lundin R, Rossi G, Masavon W, Patel D, et al. Predictors of treatment failure in HIV-positive children receiving combination antiretroviral therapy: cohort data from Mozambique and Uganda. J Pediatr Infect Dis Soc. 2015;4(1):39–48. https://doi.org/10.1097/jpids.0000000000000302.
18. Pillay P, Ford N, Shubber Z, Fernand MA. Outcomes for Elavirisen versus Nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013;8(7):e68995. https://doi.org/10.1371/journal.pone.068995.
19. Mjelema EM, Kisege R, Aboud S. Detecting virological failure in HIV-infected Tanzanian children. SAMJ South Afr Med J. 2014;104(10):696–9. https://doi.org/10.7196/SAMJ.7807.
20. Neuwinkel PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr. 1999; 2005;38:445–8.
21. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS Lond Engl. 2001; 15(16):2109–17. https://doi.org/10.1097/00002030-200111000-00006.
22. Marhefka SL, Koenig LJ, Allison S, Bachanis P, Bulterys M, Bettica L, et al. Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. AIDS Patient Care STDs. 2008;22(8):637–47. https://doi.org/10.1089/apc.2007.0110.
23. Haberer JE, Kiwanuka J, Nansera D, Ragland K, Melling S, Bangsberg DR. Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected Ugandan children. PLoS One. 2012;7(5):e36737. https://doi.org/10.1371/journal.pone.036737.
24. Natukunda J, Kribira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional study. Trop Med Health. 2019;47(1):18. https://doi.org/10.1186/s41182-019-0135-z.
25. About us – Brief History. http://kbth.gov.gh/brief-history/ (Accessed 3 Jan 2019).
26. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2016 http://www.desilbris.ca/I10089566 (Accessed 11 Apr 2019).
27. Heinisch O, Cochran, W. G.: sampling techniques, 2., Aufl. John Wiley and Sons, New York, London 1963. Preis s. Biorn Z. 1965/7:203.
28. Nichols JS, Kykaliides TC, Antwi S, Renner L, Lartey M, Larhey M, Seaneke OA, et al. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care. 2019;31(1):25–34. Available from: https://www.tandfonline.com/doi/full/10.1080/09540121.201 8.124113. Accessed 5 Feb 2019.
29. WHO | Antiretroviral therapy of HIV infection in infants and children: towards universal access. WHO. http://www.who.int/hiv/pub/guidelines/art/ en/ (Accessed 23 May 2017).

Afrane et al. BMC Infectious Diseases (2021) 21:731
Page 10 of 11
30. Ending AIDS: progress towards the 90–90–90 targets | UNAIDS. http://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017 (Accessed 14 Feb 2019).

31. Tucker JD, Bien CH, Easterbrook PJ, Doherty MC, Penazzato M, Vittoria M, et al. Optimal strategies for monitoring response to antiretroviral therapy in HIV-infected adults, adolescents, children and pregnant women: a systematic review. AIDS Lond Engl 2014;28(Suppl 2):S151–60.

32. Makadzange AT, Higgins-Biddle M, Chimukangara B, Birir R, Gordon M, Mahanza T, et al. Clinical, virologic, immunologic outcomes and emerging HIV drug resistance patterns in children and adolescents in public ART Care in Zimbabwe. PLoS One. 2015;10(12):e0144057. https://doi.org/10.1371/journal.pone.0144057.

33. Bavaro DF, Di Carlo D, Rossetti B, Buzzizone B, Vicentì I, Pontetì E, et al. Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-infected patients enrolled in ARCA. Antivir Ther. 2010;25(2):61–71. https://doi.org/10.3851/mp0349.

34. Chimukangara B, Kharsany ABM, Lessells RJ, Naidoo K, Rhee S-Y, Manasa J, et al. Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa. AIDS Res Hum Retrovi. 2019;35(2):129–38. https://doi.org/10.1097/AID.0000000000002020.

35. McCluskey SM, Lee GQ, Kamelian K, Kembabazi A, Musinguzi N, Bwana MB, et al. Factors associated with Virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis. 2009;9(1):81. https://doi.org/10.1186/1471-2334-9-81.

36. Rajian M, Gill PS, Chaudhary U. Effect of tuberculosis co-infection on virological failure. Am Fam Physician. 2016;94(9):708–16.

37. Izudi J, Alioni S, Kerukadho E, Ndingutse D. Virological failure reduced with HIV-lesusceptibility disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in northwestern Uganda. BMC Infect Dis. 2009;9(1):81. https://doi.org/10.1186/1471-2334-9-81.

38. Bayu B, Taniku A, Bulti AB, Habitu YA, Dero T, Teshome DF. Determinants of virological failure among patients on highly active antiretroviral therapy in University of Goedner Referral Hospital, Northwest Ethiopia: a case-control study. HIVAIDS - Res Palliat Care. 2017. https://doi.org/10.2147/HIVAIDS.S139516.

39. Legarth R, Omlund LH, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, et al. Educational attainment and risk of HIV infection, response to antiretroviral treatment, and mortality in HIV-infected patients. AIDS Lond Engl. 2014;28(3):387–96. https://doi.org/10.1097/QAD.0000000000000332.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

48. Mensah E. Predictors of Virological failure among children infected with HIV-1 on Haart at KATH. 2017. http://ir.knust.edu.gh:8080/handle/123456789/10001 (Accessed 4 Feb 2019).

49. Measurement Issues in Using Pharmacy Records to Calculate Adherence to Antiretroviral Drugs: HIV Clinical Trials: Vol 14, No 2. https://www.tadonline.com/doi/abs/10.3851/imp3349. Accessed 2 Feb 2019.

50. Intasan J, Bunupuradath T, Voranthanak S, Kosalaraksa P, Hansudewewachakul R, Kanjanavanit S, et al. Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial. AIDS Patient Care STDs. 2014;28(6):296–302. https://doi.org/10.1089/apc.2013.0276.

51. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression - Cambiano - 2010 - HIV Medicine - Wiley Online Library. https://onlinelibrary. wiley.com/doi/full/10.1111/j.1468-1293.2009.00771.x. Accessed 2 Feb 2019.